Monitoring Avalo Therapeutics Inc. (AVTX) after recent insider movements


Avalo Therapeutics Inc.’s filing revealed that its 10% Owner ARMISTICE CAPITAL, LLC unloaded Company’s shares for reported $0.49 million on Jun 27. In the deal valued at $0.52 per share,937,404 shares were sold. As a result of this transaction, ARMISTICE CAPITAL, LLC now holds 731,458 shares worth roughly $ 65831.22.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Then, ARMISTICE CAPITAL, LLC sold 2,746,138 shares, generating $1,682,010 in total proceeds. Upon selling the shares at $0.61, the 10% Owner now owns 1,668,862 shares.

Before that, Caissa Capital Management ltd. bought 2,000 shares. Avalo Therapeutics Inc. shares valued at $8,289 were divested by the 10% Owner at a price of $4.14 per share. As a result of the transaction, Caissa Capital Management ltd. now holds 1,425,700 shares, worth roughly $0.13 million.

RBC Capital Mkts initiated its Avalo Therapeutics Inc. [AVTX] rating to an Outperform in a research note published on Friday, September 24, 2021; the price target was $6. PT values the company’s stock at a premium of 98.5 to its Friday closing price.

Price Performance Review of AVTX

On Friday, Avalo Therapeutics Inc. [NASDAQ:AVTX] saw its stock fall -8.60% to $0.09. On the same session, the stock had its day’s lowest price of $0.086, but rose to a high of $0.102. Over the last five days, the stock has lost -10.65%. Avalo Therapeutics Inc. shares have fallen nearly -98.19% since the year began. Nevertheless, the stocks have fallen -98.08% over the past one year. While a 52-week high of $7.00 was reached on 01/18/23, a 52-week low of $0.09 was recorded on 09/01/23. SMA at 50 days reached $0.3149, while 200 days put it at $2.7957. A total of 9.31 million shares were traded, compared to the trading of 10.43 million shares in the previous session.

Levels Of Support And Resistance For AVTX Stock

The 24-hour chart illustrates a support level at 0.0843, which if violated will result in even more drops to 0.0771. On the upside, there is a resistance level at 0.1003. A further resistance level may holdings at 0.1091. The Relative Strength Index (RSI) on the 14-day chart is 27.39, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0121, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 94.38%. Stochastics %K at 10.71% indicates the stock is a buying.

How much short interest is there in Avalo Therapeutics Inc.?

A steep rise in short interest was recorded in Avalo Therapeutics Inc. stocks on Aug 14, 2023, growing by 70350.0 shares to a total of 0.96 million shares. Yahoo Finance data shows the prior-month short interest on Jul 13, 2023 was 0.89 million shares. There was a rise of 7.35%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 6.65% of the overall stock float, the days-to-cover ratio (short ratio) rose to 0.32.

Avalo Therapeutics Inc. [AVTX] – Who Are The Largest Shareholders?

In filings from Nantahala Capital Management LLC, it is revealed that the company now owns 556,202 shares, or roughly 4.21% of the outstanding AVTX shares. In other words, the investor’s shares have fallen by -252,642 from its previous 13-F filing of 808844.0.. Over the last quarter, Geode Capital Management LLC purchased 29,638 shares of Avalo Therapeutics Inc., while Millennium Management LLC bought -28,386 shares. At present, Virtu Financial BD LLC is holding 32,593 shares valued at $6519.0. SSgA Funds Management, Inc. owned 25,643 shares of the company at the time of its most recent 13F filing, worth $5129.0.

According to FactSet, Avalo Therapeutics Inc.’s share price will average $0.75 in the next year, based on opinions of analysts polled by the firm. This is up nearly 650.0 percent from its previous closing price of $0.10. Analysts expect Avalo Therapeutics Inc. stock to reach the higher price of $0.75, while the lowest price estimate is $0.75. However, 1 analyst have rated AVTX stock as a Hold in their predictions for 2023.


Please enter your comment!
Please enter your name here